There was evidence (P-value <1.72 × 10−3; 0.05/29 cancer types (12 overall cancers plus 17 subtypes)) for an effect of higher genetically predicted liver fat on liver cancer risk (IVW OR = 4.09, 95% CI = 2.29 to 7.28), higher genetically predicted pancreas fat on endometrioid ovarian cancer risk (IVW OR = 1.99, 95% CI = 1.37 to 2.90), and for a protective effect of higher genetically predicted ASAT on luminal B/HER2-negative-like (IVW OR = 0.54, 95% CI = 0.40 to 0.73) and triple-negative or basal-like breast cancer risk (IVW OR = 0.43, 95% CI = 0.26 to 0.71; Figure 2, Table S5). The gene discussed is ERBB2; the disease is ovarian endometrioid adenocarcinoma.